

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

**CLARIFICATION AND COMPLETION ANNOUNCEMENT
DISCLOSEABLE TRANSACTIONS
ACQUISITIONS OF ASSETS IN SWITZERLAND AND THE UNITED
KINGDOM THROUGH ITS SUBSIDIARIES**

Reference is made to the announcement (“**Announcement**”) dated 2 September 2025 of EuroEyes International Eye Clinic Limited in relation to the discloseable transactions regarding the acquisitions of assets in Switzerland and the United Kingdom through its subsidiaries.

Capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

1. CLARIFICATION OF THE ANNOUNCEMENT

The Board would also like to clarify and provide additional information in respect of the Announcement.

DEFINITION

The Board would like to clarify that the definition of “Minority EuroEyes Swiss Shareholders” shall be read as follows:

| | |
|--|---|
| “Minority EuroEyes Swiss Shareholders” | the minority shareholders of EuroEyes Swiss after Completion, including Mr. David Holenstein and Mr. Ulrich Harmuth, being two of the persons designated by Betterview Swiss to be transferred and assigned with shares in EuroEyes Swiss pursuant to the Swiss Agreement |
|--|---|

ULTIMATE BENEFICIAL OWNERS OF BETTERVIEW SWISS AND BETTERVIEW UK

The Board would like to clarify that, as at the date of the Announcement, Betterview UK was a wholly-owned subsidiary of Betterview Swiss while Betterview Swiss had a total of 44 shareholders with Javier Garcia, Ulrich Harmuth and Walter Koller as its largest shareholders holding approximately 23.3%, 11.0% and 8.2% interests therein, respectively, and Mr. David Holenstein holding approximately 3.51% interests therein, and there was no shareholder having an interest of more than one-third in Betterview Swiss.

THE SWISS AGREEMENT

Swiss Consideration Shares

Pursuant to the Swiss Agreement, it is anticipated that the Swiss Consideration Shares to be issued to Betterview Swiss will be distributed by Betterview Swiss to its 44 shareholders upon Completion in proportion to their then shareholdings in Betterview Swiss.

Management share awards

The Board would like to clarify that, upon the completion of the Swiss Agreement, EuroEyes Swiss would assign and transfer 511,363 and 511,363 ordinary shares of CHF0.01 each in the share capital of EuroEyes Swiss, representing approximately 4.5% and 4.5% of the equity interests therein, to Mr. David Holenstein and Mr. Ulrich Harmuth, respectively, as compensation and award to them for their continued employment with EuroEyes Swiss to run the business in relation to the Swiss Assets.

Shareholding structure of EuroEyes Swiss upon Completion

The following table sets out the shareholding structure of EuroEyes Swiss upon the completion of the Swiss Agreement:

| Name of shareholder | Class of shares | Number of shares held | % |
|--|-------------------|-----------------------|-------------|
| The Company | Ordinary shares | 8,977,274 | 79% |
| Mr. David Holenstein | Ordinary shares | 511,363 | 4.5% |
| Mr. Ulrich Harmuth | Ordinary shares | 511,363 | 4.5% |
| Minority EuroEyes Swiss Shareholders (including Mr. David Holenstein and Mr. Ulrich Harmuth) | Non-voting shares | 1,363,636 | 12% |
| Total: | | 11,363,636 | 100% |

THE SWISS ASSETS

Composition of the Swiss Assets

The Board would like to clarify that there was a typographical error in the Announcement about the composition of the Swiss Assets such that one of the medical clinics for refractive surgery was mistakenly written as “Lucerne” and shall be read as “Basel”.

Book value of assets, revenues and profits (losses) of the Swiss Assets

The Board would like to clarify that there was a typographical error in the Announcement about the gross profit of the Swiss Assets for the six months ended 30 June 2025 which shall be “CHF1,357,733.71” instead of “CHF666,072.31”.

For the sake of clarity, the entire table setting out the revenue and gross profit attributable to the Swiss Assets for the year ended 31 December 2024 and for the six months ended 30 June 2025 that have been extracted from the financial statements of Betterview Swiss is reproduced below:

| | For the year ended 31 December 2024 | For the six months ended 30 June 2025 |
|---------------------|--|--|
| Revenue | CHF15,749,313.64 | CHF6,463,800.70 |
| Gross profit | CHF4,489,110.29 | CHF1,357,733.71 |

The Board would also like to provide additional financial information in relation to the Swiss Assets. The following table sets out the net profit (before and after taxation) attributable to the Swiss Assets for the year ended 31 December 2023, the year ended 31 December 2024 and for the six months ended 30 June 2025:

| | For the year ended 31 December 2023 | For the year ended 31 December 2024 | For the six months ended 30 June 2025 |
|------------------------------|--|--|--|
| Net profit (before taxation) | CHF 46,401.50 | CHF 2,715,870.09 | (CHF 678,008.15) |
| Net profit (after taxation) | CHF 46,172.86 | CHF 2,712,343.50 | (CHF 679,364.96) |

THE UK ASSETS

Book value of assets, revenues and profits (losses)

The Board would like to provide additional financial information in relation to the UK Assets. The following table sets out the net profit (before and after taxation) attributable to the UK Assets from 21 August 2023 (i.e., the date of incorporation of Betterview UK) to 31 December 2023, the year ended 31 December 2024 and for the six months ended 30 June 2025:

| | From 21 August 2023 to 31 December 2023 | For the year ended 31 December 2024 | For the six months ended 30 June 2025 |
|------------------------------|--|--|--|
| Net profit (before taxation) | CHF Nil ^(Note) | (CHF 599,450.90) | (CHF 512,106.65) |
| Net profit (after taxation) | CHF Nil ^(Note) | (CHF 599,450.90) | (CHF 512,106.65) |

Note: During the period from 21 August 2023 to 31 December 2023, Betterview UK did not commence operation until January 2024.

Basis of the Net Profits of the Swiss Assets and the UK Assets

The Board would also like to draw the attention of the Shareholders and the potential investors of the Company that Betterview Swiss and Betterview UK did not keep separate books for the Swiss Assets and the UK Assets and that the net profit figures disclosed herein were calculated by the management of Betterview Swiss and Betterview UK on a proforma basis, based on revenues and costs extracted from the Betterview Swiss and Betterview UK accounts using assumptions to allocate overhead costs in a manner consistent with the future structure of the Swiss Assets and the UK Assets.

THE UK CONSIDERATION

The Board would like to clarify that the UK Consideration was arrived at after arm's length negotiations between EuroEyes UK and the Betterview UK on normal commercial terms with reference to the book value of the UK Assets of CHF1,894,703.67 as at 31 August 2025 and having taken into account that the UK Business is currently loss making and Betterview UK, which was set up in August 2023, has been in operation for years and has still not reached cash breakeven. For these reasons, a substantial discount to the book value of the UK Assets was agreed between Betterview UK and EuroEyes UK as the basis of the UK Consideration.

Saved as disclosed and clarified above, all information set out in the Announcement remains unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Announcement.

2. COMPLETION OF THE SWISS AGREEMENT

The Company is also pleased to announce that all the conditions precedent of the Swiss Agreement have been satisfied, and the Completion of the Swiss Agreement took place on 13 October 2025 in accordance with its terms and conditions.

Upon Completion of the Swiss Agreement, EuroEyes Swiss assigned and transferred 511,363 and 511,363 ordinary shares of CHF0.01 each in the share capital of EuroEyes Swiss, representing approximately 4.50% and 4.50% of the equity interests therein, to Mr. David Holenstein and Mr. Ulrich Harmuth, respectively, as compensation and award to them for their continued employment with EuroEyes Swiss to run the business in relation to the Swiss Assets.

Upon Completion of the Swiss Agreement, the Company (as major shareholder of the EuroEyes Swiss), the Minority EuroEyes Shareholder and EuroEyes Swiss entered into the Shareholders' Agreement to govern their respective rights and obligations together with the grant of the Put Option. The total number of shares of EuroEyes Swiss under the Put Option is 2,386,362, comprising 1,363,636 non-voting shares and 1,022,726 ordinary shares.

On 11 December 2025, the Company and the Minority EuroEyes Shareholders signed a side letter ("**Side Letter**") whereby the Minority EuroEyes Shareholders agreed that in case the exercise price per share ("**Option Purchase Price**") of the Put Option is calculated to be equal to or more than CHF5.44 at anytime after the Put Option becomes exercisable, the Minority EuroEyes Shareholders as holders of the Put Option shall (a) only exercise the Put Option at the Option Purchase Price of CHF5.44; or (b) not exercise the Put Option unless and until the Company consents to the purported exercise of the Put Option in writing. In case of (b) above, the Company shall further negotiate with the Minority EuroEyes Shareholders again in order to come up with a proposal at fair and reasonable terms for the Minority EuroEyes Shareholders to exit the shares of EuroEyes Swiss then held by them.

Listing Rules Implications

The grant of Put Option under the Shareholders' Agreement constitutes a transaction under Rules 14.72 (1) and 14.73 of the Listing Rules.

Given that the Option Purchase Price has been capped at CHF5.44 per share pursuant to the Side Letter, the highest monetary value of the Put Option (after aggregated with the Swiss Consideration and the UK Consideration) will make one or more of the applicable percentage ratios (as defined in the Listing Rules) exceed 5% but less than 25%, accordingly, the grant of the Put Option constitutes a discloseable transaction of the Company and is subject to the announcement requirement under Chapter 14 of the Listing Rules but exempt from shareholders' approval requirement.

By order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 30 January 2026

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Mr. Jannik Jonas Slot Jørgensen, Professor Dan Zoltan Reinstein and Mr. Marcus Huascar Bracklo as executive Directors; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.